

# Fabio Angeli

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11203906/fabio-angeli-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

112  
papers

4,822  
citations

32  
h-index

68  
g-index

148  
ext. papers

5,807  
ext. citations

4.8  
avg. IF

6.1  
L-index

#	Paper	IF	Citations
112	Renin Angiotensin System Blockers and Risk of Mortality in Hypertensive Patients Hospitalized for COVID-19: An Italian Registry.. <i>Journal of Cardiovascular Development and Disease</i> , <b>2022</b> , 9,	4.2	3
111	Soluble CD40 ligand and outcome in patients with coronary artery disease undergoing percutaneous coronary intervention. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2022</b> , 60, 118-126	5.9	
110	Benefits of more intensive versus less intensive blood pressure control. Updated trial sequential analysis.. <i>European Journal of Internal Medicine</i> , <b>2022</b> ,	3.9	2
109	Chronic Kidney Disease and Left Ventricular Hypertrophy. Potent Modifiers of the Prognostic Impact of Circadian Blood Pressure Changes.. <i>Hypertension</i> , <b>2022</b> , HYPERTENSIONAHA12218969	8.5	
108	Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis. <i>Journal of Cardiovascular Development and Disease</i> , <b>2022</b> , 9, 150	4.2	1
107	Electrocardiographic features of patients with COVID-19: One year of unexpected manifestations. <i>European Journal of Internal Medicine</i> , <b>2021</b> ,	3.9	3
106	Pharmacotherapy for hypertensive urgency and emergency in COVID-19 patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 1-8	4	2
105	SARS-CoV-2 vaccines: Lights and shadows. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 88, 1-8	3.9	34
104	Joint effect of heart failure and coronary artery disease on the risk of death during hospitalization for COVID-19. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 89, 81-86	3.9	5
103	Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation. <i>European Heart Journal</i> , <b>2021</b> , 42, 2019	9.5	2
102	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> ,	3.9	2
101	An update on antithrombotic therapy in atrial fibrillation patients in long-term ambulatory setting after percutaneous coronary intervention: where do we go from here?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 2033-2051	4	1
100	Aprocitan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension. <i>Cardiology and Therapy</i> , <b>2021</b> , 10, 397-406	2.8	4
99	Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 90, 111-113	3.9	9
98	The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 93, 28-34	3.9	7
97	Management of hypertension in the very old: an intensive reduction of blood pressure should be achieved in most patients. <i>Journal of Human Hypertension</i> , <b>2020</b> , 34, 551-556	2.6	2
96	COVID-19: ACE2centric Infective Disease?. <i>Hypertension</i> , <b>2020</b> , 76, 294-299	8.5	39

95	Severity of COVID-19: The importance of being hypertensive. <i>Monaldi Archives for Chest Disease</i> , <b>2020</b> , 90,	2.7	4
94	Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus. <i>Journal of Hypertension</i> , <b>2020</b> , 38, 1190-1191	1.9	17
93	Alcohol intake and atrial fibrillation: A new topic in gender medicine. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 76, 23-25	3.9	0
92	Treatment strategies for isolated systolic hypertension in elderly patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 1713-1723	4	2
91	Electrocardiographic features of patients with COVID-19 pneumonia. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 78, 101-106	3.9	70
90	Optimal Use of the Non-Inferiority Trial Design. <i>Pharmaceutical Medicine</i> , <b>2020</b> , 34, 159-165	2.3	5
89	Hypertensive urgencies and emergencies: Misconceptions and pitfalls. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 71, 15-17	3.9	5
88	Non-inferiority Trial Design in Drug Development: A Primer for Cardiovascular Healthcare Professionals. <i>American Journal of Cardiovascular Drugs</i> , <b>2020</b> , 20, 229-238	4	2
87	The 2020 International Society of Hypertension global hypertension practice guidelines - key messages and clinical considerations. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 82, 1-6	3.9	20
86	The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 76, 14-20	3.9	652
85	Device-Pocket Hematoma After Cardiac Implantable Electronic Devices. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2020</b> , 13, e008372	6.4	4
84	European and US guidelines for arterial hypertension: similarities and differences. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 63, 3-8	3.9	12
83	Electrocardiography for diagnosis of left ventricular hypertrophy in hypertensive patients with atrial fibrillation. <i>International Journal of Cardiology: Hypertension</i> , <b>2019</b> , 1, 100004	1.6	2
82	Role of Ambulatory Blood Pressure Monitoring in Prehypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , <b>2019</b> , 471-491	0.1	
81	PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 533-541	5.5	3
80	Hypertension and Atrial Fibrillation: Doubts and Certainties From Basic and Clinical Studies. <i>Circulation Research</i> , <b>2018</b> , 122, 352-368	15.7	76
79	Left Ventricular Hypertrophy and Coronary Artery Calcifications: A Dangerous Duet?. <i>American Journal of Hypertension</i> , <b>2018</b> , 31, 287-289	2.3	4
78	Role and prognostic value of individual ambulatory blood pressure components in chronic kidney disease. <i>Journal of Human Hypertension</i> , <b>2018</b> , 32, 625-632	2.6	4

77	Hypertensive Heart Disease. <i>Updates in Hypertension and Cardiovascular Protection</i> , <b>2018</b> , 189-212	0.1	
76	Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain. <i>Expert Review of Clinical Pharmacology</i> , <b>2018</b> , 11, 1073-1084	3.8	13
75	How Low Should We Go With Blood Pressure?. <i>Circulation Research</i> , <b>2017</b> , 120, 27-29	15.7	4
74	Impact of Chamber Dilatation on the Prognostic Value of Left Ventricular Geometry in Hypertension. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	10
73	More Versus Less Intensive Blood Pressure-Lowering Strategy: Cumulative Evidence and Trial Sequential Analysis. <i>Hypertension</i> , <b>2016</b> , 68, 642-53	8.5	63
72	Prognostic Value of Ambulatory Blood Pressure Monitoring <b>2016</b> , 165-191		
71	The 2014 hypertension guidelines: implications for patients and practitioners in Asia. <i>Heart Asia</i> , <b>2015</b> , 7, 21-5	1.9	12
70	Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease. <i>Hypertension</i> , <b>2015</b> , 65, 108-14	8.5	52
69	Left ventricular hypertrophy and obesity: only a matter of fat?. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2015</b> , 22, 29-41	2.9	24
68	The prognostic legacy of left ventricular hypertrophy: cumulative evidence after the MAVI study. <i>Journal of Hypertension</i> , <b>2015</b> , 33, 2322-30	1.9	17
67	Usefulness of QRS voltage correction by body mass index to improve electrocardiographic detection of left ventricular hypertrophy in patients with systemic hypertension. <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 427-32	3	26
66	Clinical utility of ambulatory blood pressure monitoring in the management of hypertension. <i>Expert Review of Cardiovascular Therapy</i> , <b>2014</b> , 12, 623-34	2.5	14
65	Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease. <i>Hypertension</i> , <b>2014</b> , 63, 475-82	8.5	25
64	Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2013</b> , 9, 379-85	5.5	16
63	Response to Morning Surge, Dipping, and Sleep-Time Blood Pressure as Prognostic Markers of Cardiovascular Risk. <i>Hypertension</i> , <b>2013</b> , 61,	8.5	2
62	Hypertension and the J-curve phenomenon: implications for tight blood pressure control. <i>Hypertension Research</i> , <b>2013</b> , 36, 109-11	4.7	12
61	Very early initiation of statin therapy and mortality in patients with acute coronary syndrome. <i>Acute Cardiac Care</i> , <b>2012</b> , 14, 34-9		8
60	Aggressive blood pressure reduction in patients at high vascular risk: is it dangerous?. <i>Italian Journal of Medicine</i> , <b>2012</b> , 6, 302-306	0.5	

59	Fixed-dose combination therapy in hypertension: cons. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2012</b> , 19, 51-4	2.9	13
58	Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. <i>Therapeutic Advances in Cardiovascular Disease</i> , <b>2012</b> , 6, 81-91	3.4	28
57	Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview. <i>Expert Opinion on Drug Safety</i> , <b>2012</b> , 11, 659-70	4.1	12
56	The evolution and refinement of traditional risk factors for cardiovascular disease. <i>Cardiology in Review</i> , <b>2012</b> , 20, 118-29	3.2	39
55	Finding a place for aliskiren in the wide spectrum of blood pressure lowering agents. <i>Hypertension Research</i> , <b>2012</b> , 35, 17-9	4.7	1
54	Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. <i>Hypertension</i> , <b>2012</b> , 60, 34-42	8.5	208
53	Angiotensin-converting enzyme inhibitors <b>2012</b> , 14-29		
52	Fixed-Dose Combination Therapy in Hypertension <b>2012</b> , 19, 51		2
51	Clinical Significance of the Blood Pressure Changes from Day to Night. <i>Current Hypertension Reviews</i> , <b>2011</b> , 7, 13-19	2.3	1
50	Emerging therapies in the management of hypertensive patients with osteoarthritis. <i>Clinical Investigation</i> , <b>2011</b> , 1, 125-136		1
49	Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2011</b> , 7, 115-28	5.5	8
48	Diuretic treatment of hypertension. <i>Diabetes Care</i> , <b>2011</b> , 34 Suppl 2, S313-9	14.6	32
47	Aliskiren versus ramipril in hypertension. <i>Therapeutic Advances in Cardiovascular Disease</i> , <b>2010</b> , 4, 193-200	9.4	19
46	Angiotensin receptor blockers in hypertension. New insights from Japan. <i>Hypertension Research</i> , <b>2010</b> , 33, 394-7	4.7	6
45	Neutrophil count for the identification of postmenopausal hypertensive women at increased cardiovascular risk. <i>Obstetrics and Gynecology</i> , <b>2010</b> , 115, 695-703	4.9	9
44	Masked hypertension: evaluation, prognosis, and treatment. <i>American Journal of Hypertension</i> , <b>2010</b> , 23, 941-8	2.3	78
43	Treatment strategies for osteoarthritis patients with pain and hypertension. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2010</b> , 2, 229-40	3.8	14
42	The optimal blood pressure target for patients with coronary artery disease. <i>Current Cardiology Reports</i> , <b>2010</b> , 12, 302-6	4.2	9

41	Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. <i>Vascular Health and Risk Management</i> , <b>2009</b> , 5, 411-27	4.4	28
40	Home Blood Pressure Measurements Will Not Replace 24-Hour Ambulatory Blood Pressure Monitoring. <i>Hypertension</i> , <b>2009</b> , 54, 188-95	8.5	51
39	The emerging role of high-density lipoprotein cholesterol in hypertension trials. <i>Journal of Hypertension</i> , <b>2009</b> , 27, 458-60	1.9	2
38	Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. <i>Lancet, The</i> , <b>2009</b> , 374, 525-33	4.0	302
37	Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. <i>European Heart Journal</i> , <b>2009</b> , 30, 679-88	9.5	47
36	Effects of barnidipine on blood pressure and left ventricular diastolic function in patients with hypertension and metabolic syndrome: A 12-week, open-label noncomparison study. <i>Current Therapeutic Research</i> , <b>2008</b> , 69, 207-20	2.4	3
35	Prognostic value of circadian blood pressure changes in relation to differing measures of day and night. <i>Journal of the American Society of Hypertension</i> , <b>2008</b> , 2, 88-96		11
34	The Clinical Significance of New-Onset Diabetes Mellitus in Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2008</b> , 15, 1-3	2.9	0
33	Optimizing the definition of dippers and nondippers: is a 70-86% full glass empty?. <i>Journal of Hypertension</i> , <b>2008</b> , 26, 630-2	1.9	3
32	Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. <i>Journal of Hypertension</i> , <b>2008</b> , 26, 1282-9	1.9	99
31	Is the definition of daytime and nighttime blood pressure prognostically relevant?. <i>Blood Pressure Monitoring</i> , <b>2008</b> , 13, 153-5	1.3	18
30	The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. <i>Vascular Health and Risk Management</i> , <b>2008</b> , 4, 971-81	4.4	62
29	Does brachial pulse pressure predict coronary events?. <i>Advances in Cardiology</i> , <b>2007</b> , 44, 150-159		8
28	Ambulatory blood pressure for cardiovascular risk stratification. <i>Circulation</i> , <b>2007</b> , 115, 2091-3	16.7	46
27	New-onset diabetes, antihypertensive treatment, and outcome. <i>Hypertension</i> , <b>2007</b> , 50, 459-60	8.5	17
26	Ambulatory blood pressure and cardiovascular outcome in relation to perceived sleep deprivation. <i>Hypertension</i> , <b>2007</b> , 49, 777-83	8.5	96
25	The clinical significance of white-coat and masked hypertension. <i>Blood Pressure Monitoring</i> , <b>2007</b> , 12, 387-9	1.3	43
24	Estimate of white-coat effect and arterial stiffness. <i>Journal of Hypertension</i> , <b>2007</b> , 25, 827-31	1.9	24

23	Echocardiographic left ventricular hypertrophy in hypertension: marker for future events or mediator of events?. <i>Current Opinion in Cardiology</i> , <b>2007</b> , 22, 329-34	2.1	55
22	Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. <i>American Journal of Hypertension</i> , <b>2007</b> , 20, 154-61	2.3	128
21	Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: the HEART Survey study. <i>American Journal of Hypertension</i> , <b>2007</b> , 20, 997-1004	2.3	29
20	Prognostic Value of Ambulatory Blood Pressure Monitoring <b>2007</b> , 225-252		
19	Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. <i>American Journal of Hypertension</i> , <b>2006</b> , 19, 493-9	2.3	48
18	Is the development of diabetes with antihypertensive therapy a problem?--Pro. <i>Journal of Clinical Hypertension</i> , <b>2006</b> , 8, 120-6	2.3	7
17	Antihypertensive drugs and coronary artery disease : evidence from controlled trials. <i>High Blood Pressure and Cardiovascular Prevention</i> , <b>2005</b> , 12, 119-24	2.9	
16	White-coat hypertension in adults. <i>Blood Pressure Monitoring</i> , <b>2005</b> , 10, 301-5	1.3	44
15	The natural history of white-coat hypertension in the long term. <i>Blood Pressure Monitoring</i> , <b>2005</b> , 10, 65-6	1.3	7
14	New-onset diabetes in treated hypertensive patients. <i>Current Hypertension Reports</i> , <b>2005</b> , 7, 174-9	4.7	27
13	Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. <i>Hypertension</i> , <b>2005</b> , 46, 386-92	8.5	288
12	Short- and long-term incidence of stroke in white-coat hypertension. <i>Hypertension</i> , <b>2005</b> , 45, 203-8	8.5	230
11	How can we use the results of ambulatory blood pressure monitoring in clinical practice?. <i>Hypertension</i> , <b>2005</b> , 46, 25-6	8.5	18
10	Clinical usefulness of ambulatory blood pressure monitoring. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2004</b> , 15 Suppl 1, S30-3	12.7	33
9	Adverse prognostic significance of new diabetes in treated hypertensive subjects. <i>Hypertension</i> , <b>2004</b> , 43, 963-9	8.5	398
8	Reversal of left ventricular hypertrophy: what have recent trials taught us?. <i>American Journal of Cardiovascular Drugs</i> , <b>2004</b> , 4, 369-78	4	8
7	Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. <i>American Journal of Hypertension</i> , <b>2004</b> , 17, 817-22	2.3	45
6	Association between periodontal disease and left ventricle mass in essential hypertension. <i>Hypertension</i> , <b>2003</b> , 41, 488-92	8.5	90

5	Improved cardiovascular risk stratification by a simple ECG index in hypertension. <i>American Journal of Hypertension</i> , <b>2003</b> , 16, 646-52	2.3	50
4	Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. <i>American Journal of Hypertension</i> , <b>2003</b> , 16, 895-9	2.3	208
3	Atrial fibrillation in hypertension: predictors and outcome. <i>Hypertension</i> , <b>2003</b> , 41, 218-23	8.5	238
2	Ambulatory blood pressure monitoring and prognosis in the management of essential hypertension. <i>Expert Review of Cardiovascular Therapy</i> , <b>2003</b> , 1, 79-89	2.5	8
1	Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 39, 878-85	15.1	115